Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Doug Deeth was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Apr 30
Cipher Pharmaceuticals Inc. to Report Q1, 2026 Results on May 07, 2026 Cipher Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026 Annuncio • Apr 21
Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026 Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026. Location: ontario, toronto Canada Annuncio • Mar 05
Cipher Pharmaceuticals Inc. to Report Q4, 2025 Results on Mar 12, 2026 Cipher Pharmaceuticals Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026 Annuncio • Jan 29
Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™? (Spinosad) Cipher Pharmaceuticals Inc. announced that Health Canada has accepted for review Cipher's new drug submission ("NDS") for Natroba™? (Spinosad), for the treatment of head lice and scabies. Natroba™? (Spinosad) is widely recognized as one of the most effective treatments for the two parasitic indications of head lice and sc babies in the U.S. It is superior to the widely used permethrin 1% for treating head lice and is the only treatment in the U.S. that meets the FDA's criteria for a " complete cure" (elimination of all signs and symptoms) in eradicating sc babies infestations with a single application. Cipher acquired Natroba™? (spinosad) in July 2024, and since acquisition has marketed and distributed the product in the United States ("U.S.) market, through its commercial infrastructure. Annuncio • Oct 30
Cipher Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 06, 2025 Cipher Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025 Annuncio • Aug 28
Cipher Pharmaceuticals Inc. Announces the Passing of Board Director and Chairman of Audit Committee Harold M. Wolkin Cipher Pharmaceuticals Inc. announced the passing of Harold M. Wolkin, a valued member of the Company's Board of Directors and Chairman of the Audit Committee. Mr. Wolkin was a very active member of the Board and his deep understanding of the capital markets and unwavering commitment to the Company's growth and governance were tremendously valuable to the Company. During his tenure, he played a vital role in guiding strategic initiatives, supporting management, and representing the Company and its shareholders with integrity. Harold was a very well-known and highly respective member of the Canadian capital markets community and he will truly be missed by those that knew him. Annuncio • Jul 29
Cipher Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025 Cipher Pharmaceuticals Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2025 Annuncio • May 03
Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025 Cipher Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025 Annuncio • Apr 09
Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025 Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025. Location: ontario, toronto Canada Annuncio • Mar 12
Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025 Cipher Pharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 18, 2025 Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €8.55, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 466% over the past three years. Reported Earnings • Nov 10
Third quarter 2024 earnings released: EPS: US$0.011 (vs US$0.28 in 3Q 2023) Third quarter 2024 results: EPS: US$0.011 (down from US$0.28 in 3Q 2023). Revenue: US$10.4m (up 71% from 3Q 2023). Net income: US$283.0k (down 96% from 3Q 2023). Profit margin: 2.7% (down from 116% in 3Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Nov 10
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 101% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (101% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.8% average weekly change). Profit margins are more than 30% lower than last year (60% net profit margin). Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Annuncio • Nov 04
Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024 Cipher Pharmaceuticals Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024 Annuncio • Oct 08
Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer Cipher Pharmaceuticals Inc. announced the appointment of Hamed Ghanei as Chief Business Officer. Dr. Ghanei has over 15 years of experience in specialty pharmaceuticals, venture funds, and healthcare investment banking. Throughout his career, he has led the evaluation of over 500 licensing and M&A opportunities and has been involved in five commercial product launches. He has successfully negotiated over 20 transactions with total value exceeding $1 billion. Dr. Ghanei holds a B.Sc. from the University of Waterloo, a M.Sc. in Microbiology and Biochemistry from the University of Guelph, and a Ph.D. in Medical Biophysics from the University of Toronto. Valuation Update With 7 Day Price Move • Oct 04
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €10.20, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 534% over the past three years. Valuation Update With 7 Day Price Move • Sep 13
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to €9.35, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 483% over the past three years. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €10.40, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 584% over the past three years. Reported Earnings • Aug 09
Second quarter 2024 earnings released: EPS: US$0.12 (vs US$0.12 in 2Q 2023) Second quarter 2024 results: EPS: US$0.12 (down from US$0.12 in 2Q 2023). Revenue: US$5.30m (flat on 2Q 2023). Net income: US$3.00m (down 2.5% from 2Q 2023). Profit margin: 56% (down from 58% in 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 102% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Aug 02
Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024 Cipher Pharmaceuticals Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024 New Risk • Aug 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (23% accrual ratio). Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €6.80, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 588% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.03 per share. Reported Earnings • May 10
First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023) First quarter 2024 results: EPS: US$0.21 (up from US$0.10 in 1Q 2023). Revenue: US$5.87m (up 20% from 1Q 2023). Net income: US$4.92m (up 88% from 1Q 2023). Profit margin: 84% (up from 54% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Apr 09
Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024 Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024. Valuation Update With 7 Day Price Move • Mar 21
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to €5.95, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 717% over the past three years. Reported Earnings • Mar 15
Full year 2023 earnings released: EPS: US$0.81 (vs US$1.05 in FY 2022) Full year 2023 results: EPS: US$0.81 (down from US$1.05 in FY 2022). Revenue: US$21.2m (up 2.4% from FY 2022). Net income: US$20.4m (down 24% from FY 2022). Profit margin: 96% (down from 129% in FY 2022). Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has increased by 99% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Mar 09
Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024 Cipher Pharmaceuticals Inc. announced that they will report Q4, 2023 results After-Market on Mar 14, 2024 Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to €5.30, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 772% over the past three years. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €4.30, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 481% over the past three years. Valuation Update With 7 Day Price Move • Nov 16
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to €3.62, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 505% over the past three years. Reported Earnings • Nov 12
Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.11 in 3Q 2022) Third quarter 2023 results: EPS: US$0.28 (up from US$0.11 in 3Q 2022). Revenue: US$6.07m (up 27% from 3Q 2022). Net income: US$7.03m (up 165% from 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 74% per year whereas the company’s share price has increased by 77% per year. Annuncio • Oct 28
Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023 Cipher Pharmaceuticals Inc. announced that they will report Q3, 2023 results on Nov 09, 2023 Annuncio • Sep 06
Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares. Cipher Pharmaceuticals Inc. (TSX:CPH) announces a share repurchase program. Under the substantial issuer bid, the company will repurchase up to CAD 6 million worth of its outstanding shares. The shares will be tendered at a price of not less than CAD 3.95 per share and not more than CAD 4.75 per share. The company plans to fund the offer from available cash on hand. The shares purchased under the offer will be cancelled. If the aggregate cost to purchase the tendered shares exceeds $6 million, the company will accept such shares on a pro-rata basis after giving effect to “odd lot” tenders, which will not be subject to pro-ration. The bid will expire on October 11, 2023, unless extended or withdrawn. Reported Earnings • Aug 11
Second quarter 2023 earnings released: EPS: US$0.12 (vs US$0.085 in 2Q 2022) Second quarter 2023 results: EPS: US$0.12 (up from US$0.085 in 2Q 2022). Revenue: US$5.29m (down 4.9% from 2Q 2022). Net income: US$3.07m (up 43% from 2Q 2022). Profit margin: 58% (up from 39% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth. Annuncio • Jul 29
Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023 Cipher Pharmaceuticals Inc. announced that they will report Q2, 2023 results on Aug 10, 2023 Board Change • Jun 02
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Cathy Steiner was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • May 13
First quarter 2023 earnings released: EPS: US$0.10 (vs US$0.083 in 1Q 2022) First quarter 2023 results: EPS: US$0.10 (up from US$0.083 in 1Q 2022). Revenue: US$4.89m (down 9.8% from 1Q 2022). Net income: US$2.63m (up 22% from 1Q 2022). Profit margin: 54% (up from 40% in 1Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth. Annuncio • May 05
Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023 Cipher Pharmaceuticals Inc. announced that they will report Q1, 2023 results on May 11, 2023 Reported Earnings • Mar 17
Full year 2022 earnings released: EPS: US$1.05 (vs US$0.29 in FY 2021) Full year 2022 results: EPS: US$1.05 (up from US$0.29 in FY 2021). Revenue: US$20.7m (down 5.8% from FY 2021). Net income: US$26.6m (up 243% from FY 2021). Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 105% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Feb 14
Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023 On February 10, 2022, the Board of Directors of Cipher Pharmaceuticals Inc. declared a quarterly dividend of $0.0.01875 per share to shareholders of record on February 21, 2023, payable on or about February 28, 2023. Recent Insider Transactions • Dec 18
Independent Director recently sold €56k worth of stock On the 9th of December, Christian Godin sold around 21k shares on-market at roughly €2.65 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €32k more than they bought in the last 12 months. Reported Earnings • Nov 16
Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021) Third quarter 2022 results: EPS: US$0.11 (up from US$0.03 in 3Q 2021). Revenue: US$4.79m (up 6.2% from 3Q 2021). Net income: US$2.65m (up 233% from 3Q 2021). Profit margin: 55% (up from 18% in 3Q 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 45% per year. Reported Earnings • Nov 12
Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021) Third quarter 2022 results: EPS: US$0.11 (up from US$0.03 in 3Q 2021). Revenue: US$4.79m (up 6.2% from 3Q 2021). Net income: US$2.65m (up 233% from 3Q 2021). Profit margin: 55% (up from 18% in 3Q 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 4.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 46% per year. Reported Earnings • Aug 13
Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021) Second quarter 2022 results: EPS: US$0.08 (down from US$0.10 in 2Q 2021). Revenue: US$5.56m (down 9.3% from 2Q 2021). Net income: US$2.15m (down 24% from 2Q 2021). Profit margin: 39% (down from 46% in 2Q 2021). The decrease in margin was primarily driven by lower revenue. Over the next year, revenue is forecast to grow 9.6%, compared to a 6.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 14
First quarter 2022 earnings released: EPS: US$0.08 (vs US$0.05 in 1Q 2021) First quarter 2022 results: EPS: US$0.08 (up from US$0.05 in 1Q 2021). Revenue: US$5.42m (flat on 1Q 2021). Net income: US$2.15m (up 61% from 1Q 2021). Profit margin: 40% (up from 25% in 1Q 2021). Over the next year, revenue is forecast to grow 7.0%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment improved over the past week After last week's 15% share price gain to €1.64, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 70% over the past three years. Reported Earnings • Mar 19
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: US$0.29 (up from US$0.16 in FY 2020). Revenue: US$21.9m (up 1.6% from FY 2020). Net income: US$7.76m (up 77% from FY 2020). Profit margin: 35% (up from 20% in FY 2020). The increase in margin was primarily driven by lower expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 8.5%, compared to a 8.2% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improved over the past week After last week's 19% share price gain to €1.45, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 19x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 19% over the past three years. Valuation Update With 7 Day Price Move • Dec 25
Investor sentiment improved over the past week After last week's 16% share price gain to €1.28, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 25% over the past three years. Reported Earnings • Nov 12
Third quarter 2021 earnings released: EPS US$0.03 (vs US$0.059 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$4.51m (down 6.9% from 3Q 2020). Net income: US$796.0k (down 50% from 3Q 2020). Profit margin: 18% (down from 33% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment improved over the past week After last week's 17% share price gain to €1.60, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 23% over the past three years. Valuation Update With 7 Day Price Move • Aug 19
Investor sentiment improved over the past week After last week's 19% share price gain to US$1.34, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 25x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 35% over the past three years. Reported Earnings • Aug 14
Second quarter 2021 earnings released: EPS US$0.11 (vs US$0.015 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$6.13m (up 30% from 2Q 2020). Net income: US$2.82m (up US$2.41m from 2Q 2020). Profit margin: 46% (up from 8.7% in 2Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment improved over the past week After last week's 20% share price gain to US$1.06, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 38% over the past three years. Reported Earnings • May 16
First quarter 2021 earnings released: EPS US$0.05 (vs US$0.092 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$5.45m (down 7.7% from 1Q 2020). Net income: US$1.34m (down 46% from 1Q 2020). Profit margin: 25% (down from 42% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year and the company’s share price has also fallen by 27% per year. Is New 90 Day High Low • Jan 08
New 90-day high: €0.74 The company is up 9.0% from its price of €0.68 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.71 per share. Reported Earnings • Nov 14
Third quarter 2020 earnings released: EPS US$0.06 The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: US$4.85m (down 16% from 3Q 2019). Net income: US$1.60m (up US$3.79m from 3Q 2019). Profit margin: 33% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 45% per year whereas the company’s share price has fallen by 40% per year. Analyst Estimate Surprise Post Earnings • Nov 14
Revenue beats expectations Revenue exceeded analyst estimates by 23%. Over the next year, revenue is expected to shrink by 24% compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany. Is New 90 Day High Low • Nov 10
New 90-day low: €0.59 The company is down 32% from its price of €0.87 on 12 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Is New 90 Day High Low • Oct 21
New 90-day low: €0.64 The company is down 31% from its price of €0.92 on 23 July 2020. The German market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.55 per share. Annuncio • Oct 10
Cipher Pharmaceuticals Inc. Approves the Appointment of Cathy Steiner as Director Cipher Pharmaceuticals Inc. announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier October 8, 2020. The shareholders approved the appointment of Cathy Steiner as director. Is New 90 Day High Low • Sep 28
New 90-day low: €0.69 The company is down 10.0% from its price of €0.77 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.58 per share.